NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I don’t think your conclusions are necessarily correct,

instead:

1. We don’t know the non-crossovers did better.
2. We don’t know the non-crossovers are all methylated.

What I think this shows is that most of the 24 unidentified mgmt amongst the non-crossovers probably came from early in the trial, before satisfactory mgmt methylation tests were developed. 2008

What we know so far:

Blended data: Only 38 out of 331 (11.4%) mgmt status undetermined.
Post unblinding:
NGBM: Only 11 out of 232 (4.7%) mgmt undetermined.

RGBM: Only 3 out of 64 (4.7%) mgmt undetermined.

Non-Crossover Placebos. whopping 24 out of 38 (63%) mgmt undetermined — probably mostly patients prior to good mgmt determination availability.

On another note, if you are looking at rGBM crossover patients, and instead of the NYAS slides showing time from recurrence, they had shown time from surgery or randomization, you’d see where other strong numbers are coming from.

Instead of trying to compare arms the traditional way, you need to wait for further data. Your post is simply speculation. My guess is the enrollees from 2008 to 2009 do not provide meaningful data, because they were before mgmt tests were truly helpful.